TP53 and acute myeloid leukemia: Eprenetapopt and coti-2, both aimed at reactivating p53, are currently being tested in clinical trials involving patients with acute myeloid leukemia (AML; NCT03931291) and various solid malignant tumors (NCT04383938 and NCT02433626).